pipette
ENEnglish

Uveoscleral Outflow Enhancement as a Complementary Bio-intervention after Failed Prior Trabecular Outflow Treatment: 12-Month Outcomes of Allograft-reinforced Cyclodialysis in Open Angle Glaucoma

G. Gazzard, H. Jayaram, R. Garg, T. Ianchulev, R. Stamper, J. Tsai, I. P. Singh

PreprintUso en el mundo real

En palabras de los autores

Abstract and KeywordsO_ST_ABSBackgroundC_ST_ABSEyes with open-angle glaucoma uncontrolled after a trabecular outflow procedure have limited options before progressing to bleb-forming surgery. The uveoscleral pathway is distinct, relatively pressure-independent, and conjunctiva-sparing. We report 12-month outcomes of standalone allograft-reinforced cyclodialysis in eyes with IOP that remained uncontrolled after prior trabecular outflow intervention. MethodsAnalysis of a multicentre registry (CREST; NCT05506423). Eligible eyes had at least one prior trabecular outflow procedure, no prior bleb-forming surgery, and underwent uveoscleral outflow bio-intervention with at least 12 months of follow-up. IOP reported as mean with 95% CI, medication as mean {+/-} SD. ResultsForty-seven eyes were eligible; 91.5% completed 12 months. Consistent with moderate-to-advanced glaucoma, baseline IOP was 22.5 mmHg (20.1, 24.9) on 3.0 (1.3) IOP-lowering medications, with visual field mean deviation -11.7 dB (8.1). 95.7% were pseudophakic. In the per-protocol efficacy analysis, IOP fell 6.1 mmHg (3.7, 8.6), a 25.0% reduction (15.5%, 34.5%; p < 0.001), with no increase in medication. At 12 months, the Kaplan-Meier estimate of freedom from incisional reoperation was 78.2% (61.8%, 88.2%). There were no vision-threatening, clinically significant adverse events associated with the procedure such as persistent hypotony, maculopathy or other complications. ConclusionsIn eyes with inadequately controlled IOP following prior trabecular intervention, standalone allograft-reinforced cyclodialysis was associated with clinically meaningful IOP reduction without an increase in medication burden or permanent vision loss.

Resultado principalEl resumen no menciona limitaciones.

Apareció: miércoles, 18 de noviembre. medRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.11.12.26367933